| Lessons of leprosy: the emergence of TH17 cytokines during type II reactions (ENL) is teaching us about T-cell plasticity. | |
| | |
MedLine Citation:
|
PMID: 22527432 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Leprosy was the first disease classified according to the thymus derived T-cell in the 1960s and the first disease classified by the cytokine profile as intact interferon-γ (IFN-γ) and interleukin-2 (IL2) or TH1 (tuberculoid) and deficient IFN-γ and IL2 or TH2 (lepromatous), in the 1980s. Objective: In the present study, we set out to explore the T helper 17 (TH17) lymphocyte subset, the hallmark of T-cell plasticity, in skin biopsies from patients with erythema nodosum leprosum (ENL) who were treated with thalidomide. METHOD: RNA was extracted from paraffin embedded tissue before and after thalidomide treatment of ENL and RT-PCR was performed. RESULTS: IL17A, the hallmark of TH17, was consistently seen before and after thalidomide treatment, confirming the TH17 subset to be involved in ENL and potentially up-regulated by thalidomide. CONCLUSION: A reduction in CD70, GARP, IDO, IL17B (IL-20), and IL17E (IL-25), coupled with increases in RORγT, ARNT, FoxP3, and IL17C (IL-21) following thalidomide treatment, opens the door to understanding the complexity of the immunomodulatory drug thalidomide, which can operate as an anti-inflammatory while simultaneously stimulating cell-mediated immunity (CMI). We conclude that TH17 is involved in the immunopathogenesis of ENL and that thalidomide suppresses inflammatory components of TH17, while enhancing other components of TH17 that are potentially involved in CMI. |
| | |
Authors:
|
Frank Martiniuk; Jerome Giovinazzo; Ainah U Tan; Rozana Shahidullah; Patrick Haslett; Gilla Kaplan; William R Levis |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural |
Journal Detail:
|
Title: Journal of drugs in dermatology : JDD Volume: 11 ISSN: 1545-9616 ISO Abbreviation: J Drugs Dermatol Publication Date: 2012 May |
Date Detail:
|
Created Date: 2012-04-24 Completed Date: 2012-08-15 Revised Date: 2013-02-28 |
Medline Journal Info:
|
Nlm Unique ID: 101160020 Medline TA: J Drugs Dermatol Country: United States |
Other Details:
|
Languages: eng Pagination: 626-30 Citation Subset: IM |
Affiliation:
|
Pulmonary Division, New York University Department of Medicine, New York, NY, USA. martif02@nyumc.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Biopsy Cytokines / immunology Erythema Nodosum / drug therapy, immunology* Gene Expression Regulation / drug effects Humans Interleukin-17 / genetics, immunology Leprostatic Agents / pharmacology, therapeutic use Leprosy, Lepromatous / drug therapy, immunology* Male Middle Aged RNA / metabolism Reverse Transcriptase Polymerase Chain Reaction Th17 Cells / immunology* Thalidomide / pharmacology, therapeutic use* Up-Regulation / drug effects Young Adult |
| Grant Support | |
ID/Acronym/Agency:
|
1UL1RR029893/RR/NCRR NIH HHS; UL1 RR029893/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Cytokines; 0/Interleukin-17; 0/Leprostatic Agents; 50-35-1/Thalidomide; 63231-63-0/RNA |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Where does rituximab fit in the treatment of autoimmune mucocutaneous blistering skin disease?
Next Document: A Comparison of Physicochemical Properties of a Selection of Modern Moisturizers: Hydrophilic Index ...